Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
- Details
- Category: Gilead
Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 - 1.12] on Day 14).
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
- Details
- Category: Novartis
Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with "severe" or "critical" respiratory illness caused by COVID-19.
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
- Details
- Category: AstraZeneca
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure.
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
- Details
- Category: Bayer
Bayer announced today its Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer's chloroquine and interferon beta-1b.
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Details
- Category: GlaxoSmithKline
Sanofi and GSK have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to
Boehringer Ingelheim steps up effort with Global Support Program
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has significantly stepped up its support to the fight against COVID-19. A Global Support Program has been set up to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.
More Pharma News ...
- AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
- Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries
- Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development
- GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
- Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
- Johnson & Johnson announces a lead vaccine candidate for COVID-19
- Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19